PMV Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(15,270) | $(19,128) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,610 | 2,932 |
| Depreciation | 362 | 171 |
| Accretion of discounts on marketable securities | (1,628) | (712) |
| Non-cash lease income | (92) | (89) |
| Other, net | 8 | (1) |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (169) | 2,108 |
| Operating lease right-of-use assets and liabilities | — | — |
| Accounts payable | (2,384) | (1,520) |
| Accrued expenses | 379 | 1,227 |
| Net cash used in operating activities | (16,184) | (15,012) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (594) | (156) |
| Purchases of marketable securities | (30,489) | (23,502) |
| Maturities of marketable securities | 57,249 | 73,303 |
| Net cash provided by investing activities | 26,166 | 49,645 |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of stock options and common stock issued under the 2020 EIP | — | 12 |
| Net cash provided by financing activities | — | 12 |
| Impact of exchange rates on cash, cash equivalents, and restricted cash | (34) | |
| Net increase in cash and cash equivalents | 9,948 | 34,645 |
| Cash, cash equivalents, and restricted cash | ||
| Cash, cash equivalents, and restricted cash - beginning of period | 38,528 | 109,119 |
| Cash, cash equivalents, and restricted cash - end of period | $48,476 | $143,764 |
| Supplemental disclosures of noncash investing activities | ||
| Accrued purchases of property and equipment | $6 | $298 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.